The PharmaSea project is working to make viable drug candidates of novel compounds found under the sea. LSIPR discovers how the EU-funded initiative does it.
We’re running out of new drugs. Since the 1980s, the number of new antibiotics being discovered and making it through the pipeline has been steadily dropping. Meanwhile, disease-causing microbes are becoming resistant to our old drugs.
The World Health Organization fears a “post-antibiotic era”, where common infections and minor injuries can kill. “Far from being an apocalyptic fantasy, is instead a very real possibility for the 21st century,” the organisation said in its April report on microbial resistance.
While there are efforts to tackle this problem from economic and educational angles, some researchers are turning to the world’s oceans in the search for new drug candidates.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
PharmaSea; WHO; antibiotics; generic drugs; antibiotics.